A Genotypic Test for HIV-1 Tropism Combining Sanger Sequencing with Ultradeep Sequencing Predicts Virologic Response in Treatment-Experienced Patients

PLoS ONE

Volumn 7, Issue 9, 2012, Pages

  Kagan, Ron M ^a   Johnson, Erik P ^a   Siaw, Martin ^a   Biswas, Pinaki ^b   Chapman, Douglass S ^b   Su, Zhaohui ^c   Platt, Jamie L ^a   Pesano, Rick L ^a  

^a QUEST DIAGNOSTICS NICHOLS INSTITUTE   (United States)

^b PFIZER INC   (United States)

^c Outcome Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR5; EFAVIRENZ; MARAVIROC; PLACEBO; PROTEIN VARIANT;

ADULT; ARTICLE; BIOINFORMATICS; CLASSIFICATION; CONTROLLED STUDY; FEMALE; GENETIC ALGORITHM; GENOTYPE; GENOTYPE PHENOTYPE CORRELATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; INTERMETHOD COMPARISON; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PREDICTION; REFLEX TEST; RETROSPECTIVE STUDY; TREATMENT RESPONSE; TRIPLICATE POPULATION SEQUENCING; TROFILE ENHANCED SENSITIVITY TEST; ULTRADEEP SEQUENCING; VIRAL TROPISM; VIRUS LOAD;

ADULT; AGED; ALGORITHMS; ANTI-HIV AGENTS; BIOLOGICAL ASSAY; BIOMARKERS, PHARMACOLOGICAL; CYCLOHEXANES; FEMALE; GENOTYPING TECHNIQUES; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RECEPTORS, CCR5; RECEPTORS, CXCR4; RETROSPECTIVE STUDIES; TRIAZOLES; VIRAL TROPISM;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84866887129     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0046334     Document Type: Article

References (52)

1. Berger EA, Doms RW, Fenyo EM, Korber BT, Littman DR, et al. (1998) A new classification for HIV-1. Nature 391: 240.
2. Ray N, Doms RW, (2006) HIV-1 coreceptors and their inhibitors. Curr Top Microbiol Immunol 303: 97-120.
3. Goodenow MM, Collman RG, (2006) HIV-1 coreceptor preference is distinct from target cell tropism: a dual-parameter nomenclature to define viral phenotypes. J Leukoc Biol 80: 965-972.
4. Irlbeck DM, Amrine-Madsen H, Kitrinos KM, Labranche CC, Demarest JF, (2008) Chemokine (C-C motif) receptor 5-using envelopes predominate in dual/mixed-tropic HIV from the plasma of drug-naive individuals. Aids 22: 1425-1431.
5. Connor RI, Sheridan KE, Ceradini D, Choe S, Landau NR, (1997) Change in coreceptor use correlates with disease progression in HIV-1-infected individuals. J Exp Med 185: 621-628.
6. Poveda E, Briz V, de Mendoza C, Benito JM, Corral A, et al. (2007) Prevalence of X4 tropic HIV-1 variants in patients with differences in disease stage and exposure to antiretroviral therapy. J Med Virol 79: 1040-1046.
7. Shankarappa R, Margolick JB, Gange SJ, Rodrigo AG, Upchurch D, et al. (1999) Consistent viral evolutionary changes associated with the progression of human immunodeficiency virus type 1 infection. J Virol 73: 10489-10502.
8. Daar ES, Kesler KL, Petropoulos CJ, Huang W, Bates M, et al. (2007) Baseline HIV type 1 coreceptor tropism predicts disease progression. Clin Infect Dis 45: 643-649.
9. Weiser B, Philpott S, Klimkait T, Burger H, Kitchen C, et al. (2008) HIV-1 coreceptor usage and CXCR4-specific viral load predict clinical disease progression during combination antiretroviral therapy. AIDS 22: 469-479.
10. Cooper DA, Heera J, Goodrich J, Tawadrous M, Saag M, et al. (2010) Maraviroc versus efavirenz, both in combination with zidovudine-lamivudine, for the treatment of antiretroviral-naive subjects with CCR5-tropic HIV-1 infection. J Infect Dis 201: 803-813.
11. Gulick RM, Lalezari J, Goodrich J, Clumeck N, DeJesus E, et al. (2008) Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med 359: 1429-1441.
12. Dorr P, Westby M, Dobbs S, Griffin P, Irvine B, et al. (2005) Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother 49: 4721-4732.
13. Saag M, Goodrich J, Fatkenheuer G, Clotet B, Clumeck N, et al. (2009) A double-blind, placebo-controlled trial of maraviroc in treatment-experienced patients infected with non-R5 HIV-1. J Infect Dis 199: 1638-1647.
14. Su Z, Gulick RM, Krambrink A, Coakley E, Hughes MD, et al. (2009) Response to vicriviroc in treatment-experienced subjects, as determined by an enhanced-sensitivity coreceptor tropism assay: reanalysis of AIDS clinical trials group A5211. J Infect Dis 200: 1724-1728.
15. Fatkenheuer G, Nelson M, Lazzarin A, Konourina I, Hoepelman AI, et al. (2008) Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N Engl J Med 359: 1442-1455.
16. Reeves JD, Coakley E, Petropoulos CJ, Whitcomb JM, (2009) An Enhanced-Sensitivity Trofile™ HIV Coreceptor Tropism Assay for Selecting Patients for Therapy with Entry Inhibitors Targeting CCR5: A Review of Analytical and Clinical Studies. J Viral Entry 3: 94-102.
17. Whitcomb JM, Huang W, Fransen S, Limoli K, Toma J, et al. (2007) Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism. Antimicrob Agents Chemother 51: 566-575.
18. Hwang SS, Boyle TJ, Lyerly HK, Cullen BR, (1991) Identification of the envelope V3 loop as the primary determinant of cell tropism in HIV-1. Science 253: 71-74.
19. Jensen MA, Li FS, van't Wout AB, Nickle DC, Shriner D, et al. (2003) Improved coreceptor usage prediction and genotypic monitoring of R5-to-X4 transition by motif analysis of human immunodeficiency virus type 1 env V3 loop sequences. J Virol 77: 13376-13388.
20. Sing T, Low A, Beerenwinkel N, Sander O, Cheung P, et al. (2007) Predicting HIV coreceptor usage on the basis of genetic and clinical covariates. Antivir Ther 12: 1097-1106.
21. McGovern RA, Thielen A, Mo T, Dong W, Woods CK, et al. (2010) Population-based V3 genotypic tropism assay: a retrospective analysis using screening samples from the A4001029 and MOTIVATE studies. AIDS 24: 2517-2525.
22. Poveda E, Seclen E, Gonzalez Mdel M, Garcia F, Chueca N, et al. (2009) Design and validation of new genotypic tools for easy and reliable estimation of HIV tropism before using CCR5 antagonists. J Antimicrob Chemother 63: 1006-1010.
23. Prosperi MC, Bracciale L, Fabbiani M, Di Giambenedetto S, Razzolini F, et al. (2010) Comparative determination of HIV-1 co-receptor tropism by Enhanced Sensitivity Trofile, gp120 V3-loop RNA and DNA genotyping. Retrovirology 7: 56.
24. Recordon-Pinson P, Soulie C, Flandre P, Descamps D, Lazrek M, et al. (2010) Evaluation of the genotypic prediction of HIV-1 coreceptor use versus a phenotypic assay and correlation with the virological response to maraviroc: the ANRS GenoTropism study. Antimicrob Agents Chemother 54: 3335-3340.
25. Westby M, Lewis M, Whitcomb J, Youle M, Pozniak AL, et al. (2006) Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir. J Virol 80: 4909-4920.
26. Margulies M, Egholm M, Altman WE, Attiya S, Bader JS, et al. (2005) Genome sequencing in microfabricated high-density picolitre reactors. Nature 437: 376-380.
27. Archer J, Braverman MS, Taillon BE, Desany B, James I, et al. (2009) Detection of low-frequency pretherapy chemokine (CXC motif) receptor 4 (CXCR4)-using HIV-1 with ultra-deep pyrosequencing. AIDS 23: 1209-1218.
28. Wang C, Mitsuya Y, Gharizadeh B, Ronaghi M, Shafer RW, (2007) Characterization of mutation spectra with ultra-deep pyrosequencing: application to HIV-1 drug resistance. Genome Res 17: 1195-1201.
29. Swenson LC, Mo T, Dong WW, Zhong X, Woods CK, et al. (2011) Deep sequencing to infer HIV-1 co-receptor usage: application to three clinical trials of maraviroc in treatment-experienced patients. J Infect Dis 203: 237-245.
30. Swenson LC, Mo T, Dong WW, Zhong X, Woods CK, et al. (2011) Deep V3 sequencing for HIV type 1 tropism in treatment-naive patients: a reanalysis of the MERIT trial of maraviroc. Clin Infect Dis 53: 732-742.
31. Seclen E, Soriano V, Gonzalez MM, Gomez S, Thielen A, et al. (2011) High concordance between the position-specific scoring matrix and geno2pheno algorithms for genotypic interpretation of HIV-1 tropism: V3 length as the major cause of disagreement. J Clin Microbiol 49: 3380-3382.
32. Tsibris AM, Korber B, Arnaout R, Russ C, Lo CC, et al. (2009) Quantitative deep sequencing reveals dynamic HIV-1 escape and large population shifts during CCR5 antagonist therapy in vivo. PloS one 4: e5683.
33. Vandenbroucke I, Eygen VV, Rondelez E, Vermeiren H, Baelen KV, et al. (2008) Minor Variant Detection at Different Template Concentrations in HIV-1 Phenotypic and Genotypic Tropism Testing. Open Virol J 2: 8-14.
34. Gilles A, Meglecz E, Pech N, Ferreira S, Malausa T, et al. (2011) Accuracy and quality assessment of 454 GS-FLX Titanium pyrosequencing. BMC Genomics 12: 245.
35. Huse SM, Huber JA, Morrison HG, Sogin ML, Welch DM, (2007) Accuracy and quality of massively parallel DNA pyrosequencing. Genome Biol 8: R143.
36. Wilkin TJ, Goetz MB, Leduc R, Skowron G, Su Z, et al. (2011) Reanalysis of coreceptor tropism in HIV-1-infected adults using a phenotypic assay with enhanced sensitivity. Clin Infect Dis 52: 925-928.
37. Vandekerckhove LP, Wensing AM, Kaiser R, Brun-Vezinet F, Clotet B, et al. (2011) European guidelines on the clinical management of HIV-1 tropism testing. The Lancet infectious diseases 11: 394-407.
38. Cho MW, Lee MK, Carney MC, Berson JF, Doms RW, et al. (1998) Identification of determinants on a dualtropic human immunodeficiency virus type 1 envelope glycoprotein that confer usage of CXCR4. J Virol 72: 2509-2515.
39. Nabatov AA, Pollakis G, Linnemann T, Kliphius A, Chalaby MI, et al. (2004) Intrapatient alterations in the human immunodeficiency virus type 1 gp120 V1V2 and V3 regions differentially modulate coreceptor usage, virus inhibition by CC/CXC chemokines, soluble CD4, and the b12 and 2G12 monoclonal antibodies. J Virol 78: 524-530.
40. Jabara CB, Jones CD, Roach J, Anderson JA, Swanstrom R, (2011) Accurate sampling and deep sequencing of the HIV-1 protease gene using a Primer ID. Proc Natl Acad Sci USA 108: 20166-20171.
41. Seclen E, Garrido C, Gonzalez Mdel M, Gonzalez-Lahoz J, de Mendoza C, et al. (2010) High sensitivity of specific genotypic tools for detection of X4 variants in antiretroviral-experienced patients suitable to be treated with CCR5 antagonists. J Antimicrob Chemother 65: 1486-1492.
42. Buonaguro L, Tornesello ML, Buonaguro FM, (2007) Human immunodeficiency virus type 1 subtype distribution in the worldwide epidemic: pathogenetic and therapeutic implications. J Virol 81: 10209-10219.
43. Raymond S, Delobel P, Mavigner M, Ferradini L, Cazabat M, et al. (2010) Prediction of HIV type 1 subtype C tropism by genotypic algorithms built from subtype B viruses. J Acquir Immune Defic Syndr 53: 167-175.
44. Raymond S, Delobel P, Chaix ML, Cazabat M, Encinas S, et al. (2011) Genotypic prediction of HIV-1 subtype D tropism. Retrovirology 8: 56.
45. Raymond S, Delobel P, Mavigner M, Cazabat M, Souyris C, et al. (2009) Genotypic prediction of human immunodeficiency virus type 1 CRF02-AG tropism. J Clin Microbiol 47: 2292-2294.
46. Saag M, Heera J, Goodrich J, DeJesus E, Clumeck N, et al. (2008) Reanalysis of the MERIT study with the enhanced Trofile assay (MERIT-ES). 48th Interscience Conference on Antimicrobial Agents and Chemotherapy; Washington, DC.
47. Harrigan PR, Geretti AM, (2011) Genotypic tropism testing: evidence-based or leap of faith? AIDS 25: 257-264.
48. McGovern RA, Harrigan PR, Swenson LC, (2010) Genotypic inference of HIV-1 tropism using population-based sequencing of V3. Journal of visualized experiments: JoVE.
49. Swenson LC, Moores A, Low AJ, Thielen A, Dong W, et al. (2010) Improved Detection of CXCR4-Using HIV by V3 Genotyping: Application of Population-Based and "Deep" Sequencing to Plasma RNA and Proviral DNA. J Acquir Immune Defic Syndr 54: 506-510.
50. Jensen MA, van 't Wout AB, (2003) Predicting HIV-1 coreceptor usage with sequence analysis. AIDS reviews 5: 104-112.
51. Frank DN, (2009) BARCRAWL and BARTAB: software tools for the design and implementation of barcoded primers for highly multiplexed DNA sequencing. BMC Bioinformatics 10: 362.
52. Thielen A, Lengauer T, (2012) Geno2pheno[454]: A Web Server for the Prediction of HIV-1 Coreceptor Usage from Next-Generation Sequencing Data. Intervirology 55: 113-117.